X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The combination therapy consists of Laekna’s afuresertib (LAE002), a highly selective ATP competitive AKT inhibitor in clinical trials with favorable efficacy and safety profile, and Innovent’s PD-1 inhibitor sintilimab (TYVYT), which has been approved for six indications.
Lead Product(s): Sintilimab,Afuresertib,Paclitaxel
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Laekna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
LAE002 (Afuresertib) a potent next-generation small molecule pan-AKT kinase inhibitor in combination with sintilimab and chemotherapy, targets patients with specific solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors.
Lead Product(s): Afuresertib,Sintilimab,Undisclosed
Therapeutic Area: Oncology Product Name: LAE002
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2022
Details:
Afuresertib is a clinically proven, highly potent small-molecule pan-AKT inhibitor. Afuresertib is being studied in global clinical studies in four different cancers including ovarian cancer, prostate cancer, triple-negative breast cancer, and HR+/HER2- breast cancer.
Lead Product(s): Afuresertib,Fulvestrant
Therapeutic Area: Oncology Product Name: LAE002
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2021
Details:
The companies will work together to conduct clinical studies assessing the combination of sintilimab and afuresertib (LAE002) in patients with multiple types of solid tumors that have been refractory-or failed to respond-to treatment with PD-1/PD-L1 inhibitors.
Lead Product(s): Sintilimab,Afuresertib
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Laekna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 05, 2021
Details:
According to the agreement, CMAB will provide a full spectrum of CMC services based on the recognized global quality standards for Laekna Therapeutics’ anti-PD-L1 antibody (LAE005).
Lead Product(s): LAE005,Afuresertib
Therapeutic Area: Oncology Product Name: LAE005
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Laekna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
